Status:
UNKNOWN
Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter
Lead Sponsor:
Hannover Medical School
Collaborating Sponsors:
Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick
Conditions:
COVID-19
Eligibility:
All Genders
18-99 years
Brief Summary
The purpose of this registry study is to investigate the effectiveness and safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19 patients.
Detailed Description
During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2 worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging need for treatm...
Eligibility Criteria
Inclusion
- COVID-19 infection
- Treatment with the Seraph® 100 Microbind® Affinity Blood Filter
- Voluntary consent to participate in Registry
Exclusion
- \- none
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04361500
Start Date
April 15 2020
End Date
October 1 2021
Last Update
April 24 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Teaching Hospital Brunswick
Braunschweig, Lower Saxony, Germany
2
Hannover Medical School
Hanover, Germany